SE
SEPN.US Septerna, Inc. Common Stock
- Market cap
- USD 1.90B
- P/E
- -
- P/B
- 4.63x
- ROE
- -15.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SEPN.US undervalued?
Graham numberThe Graham number of Septerna, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Septerna, Inc. Common Stock fundamental analysis
No fundamental analysis for Septerna, Inc. Common Stock yet.
Septerna, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other …
Full company profileSepterna, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Septerna, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 151K | 1.08M | 46.0M | 96.2M |
| Gross Profit | - | 151K | 1.08M | 46.0M | 95.6M |
| Operating Income | -28.0M | 2.08M | -80.8M | -80.8M | -76.5M |
| EBITDA | -27.4M | -44.7M | -70.9M | -47.3M | -55.3M |
| Net Income | -27.7M | 4.18M | -71.8M | -48.9M | -64.3M |
| EPS | -1.42 | 0.21 | -1.93 | -1.10 | -1.37 |
| Balance Sheet | |||||
| Total Assets | 36.1M | 131M | 457M | 596M | 619M |
| Total Liabilities | 80.3M | 169M | 36.5M | 214M | 191M |
| Shareholders' Equity | -44.2M | -38.4M | 420M | 382M | 428M |
| Cash & Short-term Investments | 30.6M | 88.5M | 351M | 391M | 479M |
| Total Debt | 710K | 12.6M | 25.5M | 23.6M | 22.0M |
| Cash Flow | |||||
| Operating Cash Flow | -23.3M | -38.7M | -67.5M | 110M | -82.1M |
| Capital Expenditure | 1.29M | 2.88M | 2.10M | 518K | 1.28M |
| Free Cash Flow | -24.6M | -41.6M | -69.6M | 110M | -83.4M |
| Ratios | |||||
| ROE | - | - | -17.1% | -12.8% | -15.0% |
| ROA | -76.6% | 3.2% | -15.7% | -8.2% | -10.4% |
| Net Profit Margin | - | 2,768.2% | -6,678.9% | -106.4% | -66.9% |
| Debt to Equity | - | - | 0.06x | 0.06x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Septerna, Inc. Common Stock dividends
Septerna, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Septerna, Inc. Common Stock
- Insiders 2.72%
- Institutions 97.28%
- Public & others 0.00%
- Shares outstanding 47.5M
- Free float 27.4M
Top funds holding SEPN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.05M | 2.22% | +13.69% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 908K | 1.91% | +8.67% | Sep 2026 |
| iShares Russell 2000 ETF | 559K | 1.18% | 0.00% | Oct 2026 |
| Driehaus Small Cap Growth Institutional | 480K | 1.01% | +5.84% | Sep 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 396K | 0.84% | 0.00% | Sep 2026 |
| Loomis Sayles Small Cap Growth Instl | 365K | 0.77% | 0.00% | Sep 2026 |
| Heptagon Driehaus US Sm Cp Eq C USD Acc | 348K | 0.73% | -7.62% | Sep 2026 |
| Fidelity Small Cap Index | 242K | 0.51% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 228K | 0.48% | +2.88% | Oct 2026 |
| iShares Biotechnology ETF | 227K | 0.48% | -0.19% | Oct 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 220K | 0.46% | +0.43% | Oct 2026 |
| Driehaus Micro Cap Growth USD | 161K | 0.34% | +1.42% | Sep 2026 |
| Vanguard US Opportunities Ins USD Acc | 152K | 0.32% | +3.54% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 143K | 0.30% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 141K | 0.30% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 129K | 0.27% | +1.21% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 127K | 0.27% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 111K | 0.23% | -0.41% | Sep 2026 |
| Column Small Cap Select | 109K | 0.23% | +0.70% | Sep 2026 |
| North Square Dynamic Small Cap I | 108K | 0.23% | 0.00% | Jun 2026 |
Top institutions holding SEPN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 7.00M | 14.76% | 0.00% | Jun 2026 |
| TRV GP V, LLC | 6.22M | 13.11% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 4.43M | 9.35% | +0.85% | Jun 2026 |
| TRV GP VI, LLC | 4.21M | 8.88% | 0.00% | Jun 2026 |
| Samsara BioCapital, LLC | 3.15M | 6.64% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.06M | 6.46% | +5.38% | Jun 2026 |
| BlackRock Inc | 1.93M | 4.08% | +6.03% | Jun 2026 |
| Siren, L.L.C. | 1.90M | 4.01% | -5.00% | Jun 2026 |
| PRIMECAP Management Company | 1.35M | 2.86% | +16.01% | Sep 2026 |
| venBio Select Advisor LLC | 1.34M | 2.82% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 1.31M | 2.76% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.22M | 2.58% | +2.06% | Jun 2026 |
| First Light Asset Management, LLC | 963K | 2.03% | +31.44% | Jun 2026 |
| ADAR1 Capital Management LLC | 941K | 1.98% | -13.68% | Jun 2026 |
| Geode Capital Management, LLC | 679K | 1.43% | +5.27% | Jun 2026 |
| State Street Corp | 653K | 1.38% | +3.35% | Jun 2026 |
| Loomis, Sayles & Company LP | 625K | 1.32% | 0.00% | Jun 2026 |
| Casdin Capital, LLC | 553K | 1.17% | 0.00% | Jun 2026 |
| Catalio Capital Management, LP | 536K | 1.13% | +82.14% | Jun 2026 |
| Algert Global LLC | 397K | 0.84% | +1,789.65% | Jun 2026 |
Septerna, Inc. Common Stock company profile
- Company name
- Septerna, Inc. Common Stock
- Ticker
- SEPN.US
- Exchange
- USA Stocks
- Listed since
- Oct 25, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 134
- Fiscal year end
- December
- Address
- 250 East Grand Avenue, South San Francisco, CA, United States, 94080
- Phone
- 650 338 3533
- Website
- septerna.com
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Septerna, Inc. Common Stock management
10- Dr. Jeffrey T. Finer M.D., Ph.D.Co-Founder, CEO & Director · born 1967
- Ms. Elizabeth P. Bhatt M.B.A., M.S.President & COO · born 1968
- Mr. Gilbert M. Labrucherie C.F.A., J.D.Chief Financial Officer · born 1972
- Dr. Robert J. Lefkowitz M.D.Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board · born 1944
- Dr. Arthur Christopoulos BPHARM, Ph.D.Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
- Dr. Patrick Sexton Ph.D.Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
- Mr. Richard Hansen Ph.D.Vice President of Technology
- Mr. Mark A. Wilson J.D.Chief Legal Officer · born 1972
- Mr. George Xu Ph.D.Senior Director of Corporate Development & Portfolio Strategy
- Ms. Samira ShaikhlyChief People Officer · born 1970